ArticleInternational journal of clinical practice2021

Low-dose tocilizumab is associated with improved outcome and a low risk of secondary infection in severe COVID-19 pneumonia.

Ilhami Celik et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.